Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction ... A ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

Part 3: Heart Failure With Reduced Ejection Fraction: Diagnosis and Evaluation. Part 4: Case Study: Lightheadedness, Fatigue in Man With Hypertension. Up next: Medical Management ...

Heart failure, a condition where the heart struggles to pump blood efficiently to meet the body's needs, comes in various forms and one of them, heart failure with preserved ejection fraction ...